NIMS sees positive results for chest compression alternative

In the study of a large animal model, stoppage of the heart was induced in two groups for about 18 minutes while either a modified AT-101 motion platform (stronger force than the human device) or a closed chest massage device (Thumper) was employed. Survival rates for the two groups was the same but the AT-101 group showed significantly better cardiac function and less signs of inflammation hours after resuscitation than the Thumper group.

The authors suggest that this new technology “could possibly be used as a viable alternative to conventional chest compression.”

“These findings suggest that the AT-101 technology which causes release of nitric oxide and prostacylin into the circulation during heart stoppage may ‘condition’ the heart and other organs to minimize the known adverse effects of damage caused after circulation is re-established, a phenomenon called ischemia/reperfusion injury,” said Dr Jose Adams senior investigator of the group.

He added that, “ischemia/reperfusion injury can occur after treatment of acute blood loss and sepsis, and, following heart attacks and strokes but a great deal more research needs to be done before this indication can be advocated for a clinical trial.”

The AT-101 is not currently being sold in the United States pending FDA approval. A clinical trial is planned for its intended use of temporary relief of musculoskeletal pain associated with osteoarthritis of the hips.